Overall, analysis of pooled results of experiments with all 10 patients' myeloma cells demonstrated that BMD of the myelomatous bone was 24±7% lower than pretreatment levels in saline-treated hosts (0.062±0.006 g/cm2 versus 0.083±0.006 g/cm2 pretreatment level, p<0.02), but it was 12±8% higher than pretreatment levels in the PTH-treated group (0.092±0.006 g/cm2 versus 0.084±0.005 g/cm2 pretreatment level); the difference in final BMD values of implanted bones from saline- and PTH-treated hosts was statistically significant (p<0.003) (Figure 3A). This evidence concerns the gene PTH and plasma cell myeloma.